Feedback loop maintains basal cell population

November 01, 2012

HOUSTON - (Nov. 2, 2012) - Notch - the protein that can help determine cell fate - maintains a stable population of basal cells in the prostate through a positive feedback loop system with another key protein - TGF beta (transforming growth factor beta), said Baylor College of Medicine researchers in the journal Cell Stem Cell.

"When basal cell homeostasis (or maintenance of a stable population) is disrupted, it may be part of the process that initiates prostate cancer," said Dr. Li Xin, assistant professor of molecular and cellular biology at BCM and a senior author of the report.

"Notch signaling takes different functions in different cell lineages," he said. "For example, Notch can suppress proliferation of basal cells and enhance it in luminal cells (another population of cells in the prostate)."

In studies in mice, Xin and his colleagues found that disrupting the Notch signal did not have much effect on the basal cells. However, when they disrupted both Notch and TGF beta signal, the basal cells begin to proliferate a lot," he said.

Notch is one of the important parts of the process by which basal cells sense the signals from TGF beta, said Xin.

While it might be tempting to suppress Notch signaling in an effort to prevent prostate cancer, it is probably not the best course. Systemic long-term inhibition of Notch can be toxic to intestines and result in vascular tumors.

"Once the important layer of basal cells is laid down in the prostate, the Notch-TGF beta feedback loop keeps the homeostasis of basal cells in the adult mouse prostate," said Xin.

"The disruption of this layer of basal cells may play a critical role in the initiation of prostate cancer," said Xin.
-end-
He credits graduate student Joseph Valdez in his laboratory with doing much of the work. Valdez is first author on the report. Others from BCM who took park include Li Zhang, Qingtai Su, Olga Dakhova, Yiqun Zhang, Payam Shahi, David M. Spencer, Chad J. Creighton and Michael M. Ittmann.

Funding for this work came from the National Institutes of Health. Valdez is supported by a Research Supplement to Promote Diversity in Health-Related Research from the NIH.

For more information on basic science at Baylor College of Medicine, please go to www.bcm.edu/fromthelab.

Baylor College of Medicine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.